Details

Autor(en) / Beteiligte

• Rothenberg, Marc E., MD, PhD
• Bousquet, Jean, MD

Titel

News Beyond Our Pages

Ist Teil von

• Journal of allergy and clinical immunology, 2016-12, Vol.138 (6), p.1501-1502

Ort / Verlag

St. Louis: Elsevier Limited

Erscheinungsjahr

2016

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• The safety of combination therapy with long-acting β-agonists and inhaled glucocorticoids Long-acting β-agonists (LABAs) have been shown to increase the risk of asthma-related death among adults and the risk of asthma-related hospitalization among children. [...]there are concerns about the concomitant use of inhaled glucocorticoids with LABAs. To evaluate the safety of adding salmeterol to fluticasone propionate in children with asthma, the VESTRI trial, led by Stempel et al (N Engl J Med 2016;375:840-9; http://dx.doi.org/10.1056/NEJMoa1606356), showed that with the same primary safety end point patients in the fluticasone-salmeterol group were shown to be noninferior compared to fluticasone alone (hazard ratio 1.28; 95% CI, 0.73-2.27). [...]the addition of an LABA to an inhaled glucocorticoid did not result in a higher risk of severe asthma events among children 4 to 11 years of age than inhaled glucocorticoid alone.